Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
(COV) stock logo
COV
(COV)
$0.00
$65.97
$108.57
N/AN/A3.88 million shsN/A
Ceapro Inc. stock logo
CZO
Ceapro
C$0.24
-2.0%
C$0.23
C$0.15
C$0.64
C$18.79M1.3950,166 shs47,300 shs
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$0.26
-3.8%
C$0.26
C$0.15
C$0.53
C$52.28MN/A644,760 shs384,329 shs
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
$0.29
$0.15
$0.84
$10.93M1.3160,047 shs1.27 million shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
(COV) stock logo
COV
(COV)
0.00%0.00%0.00%0.00%0.00%
Ceapro Inc. stock logo
CZO
Ceapro
0.00%-4.00%0.00%+50.00%-57.89%
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
0.00%0.00%0.00%0.00%0.00%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
0.00%0.00%0.00%0.00%-75.46%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/AN/AN/AN/A
Ceapro Inc. stock logo
CZO
Ceapro
N/AN/AN/AN/AN/AN/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
0.7989 of 5 stars
3.50.00.00.00.01.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
(COV) stock logo
COV
(COV)
N/AN/AN/AN/A
Ceapro Inc. stock logo
CZO
Ceapro
N/AN/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
3.00
Buy$2.75∞ Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/AN/A
Ceapro Inc. stock logo
CZO
Ceapro
C$11.30M1.66C$0.06 per share3.94C$0.38 per share0.63
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/A$0.32 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
(COV) stock logo
COV
(COV)
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Ceapro Inc. stock logo
CZO
Ceapro
-C$2.81M-C$0.03N/AN/A-24.86%-9.09%-6.91%5/23/2024 (Estimated)
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A-C$0.70N/AN/AN/AN/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/A
Ceapro Inc. stock logo
CZO
Ceapro
N/AN/AN/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
(COV) stock logo
COV
(COV)
N/AN/AN/A
Ceapro Inc. stock logo
CZO
Ceapro
7.82
11.00
18.88
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
35.45
2.97
2.61
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/A
9.57
9.57

Ownership

Institutional Ownership

CompanyInstitutional Ownership
(COV) stock logo
COV
(COV)
N/A
Ceapro Inc. stock logo
CZO
Ceapro
N/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
12.38%

Insider Ownership

CompanyInsider Ownership
(COV) stock logo
COV
(COV)
N/A
Ceapro Inc. stock logo
CZO
Ceapro
4.01%
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
33.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
(COV) stock logo
COV
(COV)
N/AN/AN/ANot Optionable
Ceapro Inc. stock logo
CZO
Ceapro
N/A78.29 millionN/ANot Optionable
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
161205.03 millionN/ANot Optionable
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
1669.64 million46.59 millionNot Optionable

MDNA, EMH, CZO, and COV Headlines

SourceHeadline
Medicenna Therapeutics Corp.: Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual MeetingMedicenna Therapeutics Corp.: Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
finanznachrichten.de - April 24 at 2:21 PM
Medicenna reports advancement in cancer immunotherapyMedicenna reports advancement in cancer immunotherapy
investing.com - April 11 at 9:15 AM
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceMedicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 4 at 7:59 AM
Medicenna Therapeutics Corp MDNAMedicenna Therapeutics Corp MDNA
morningstar.com - March 1 at 2:01 AM
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate UpdateMedicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
finance.yahoo.com - February 14 at 10:05 AM
Medicenna Announces Appointment of New AuditorMedicenna Announces Appointment of New Auditor
tmcnet.com - January 12 at 6:05 PM
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAFMedicenna Announces Trading on the OTCQB Under the Symbol MDNAF
finance.yahoo.com - December 19 at 7:23 AM
MDNA.TO: Overall Survival Data from Phase 2b Trial of Bizaxofusp Presented at SNO 2023…MDNA.TO: Overall Survival Data from Phase 2b Trial of Bizaxofusp Presented at SNO 2023…
finance.yahoo.com - November 20 at 5:51 PM
Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational HighlightsMedicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights
finance.yahoo.com - November 14 at 10:03 AM
MDNA.TO: Additional Confirmed PR in Phase 1/2 ABILITY Trial of MDNA11MDNA.TO: Additional Confirmed PR in Phase 1/2 ABILITY Trial of MDNA11
finance.yahoo.com - November 13 at 1:37 PM
Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
finance.yahoo.com - November 6 at 7:57 AM
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated ...Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated ...
enidnews.com - November 5 at 8:33 PM
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
finance.yahoo.com - November 3 at 1:37 PM
Why Is Medicenna Therapeutics (MDNA) Stock Down Today?Why Is Medicenna Therapeutics (MDNA) Stock Down Today?
msn.com - October 30 at 9:46 AM
Medicenna shifts to Toronto state of mind as Nasdaq listing lapsesMedicenna shifts to Toronto state of mind as Nasdaq listing lapses
fiercebiotech.com - October 27 at 1:03 PM
Medicenna Announces Nasdaq Delisting and Cutback of Management TeamMedicenna Announces Nasdaq Delisting and Cutback of Management Team
finance.yahoo.com - October 27 at 8:02 AM
Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid TumorsMedicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors
finance.yahoo.com - October 25 at 9:37 AM
Closing Bell: Medicenna Therapeutics Corp up on Thursday (MDNA)Closing Bell: Medicenna Therapeutics Corp up on Thursday (MDNA)
theglobeandmail.com - October 13 at 12:40 PM
Medicenna Therapeutics Names Humphrey Gardner CMOMedicenna Therapeutics Names Humphrey Gardner CMO
markets.businessinsider.com - October 10 at 8:13 AM
Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerMedicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
finance.yahoo.com - October 10 at 8:13 AM
Medicenna Announces Results of Annual and Special Meeting of ShareholdersMedicenna Announces Results of Annual and Special Meeting of Shareholders
finance.yahoo.com - September 28 at 6:57 PM
Medicenna Therapeutics (TSE:MDNA) Price Target Decreased by 12.14% to 3.94Medicenna Therapeutics (TSE:MDNA) Price Target Decreased by 12.14% to 3.94
nasdaq.com - September 13 at 1:31 AM
Closing Bell: Medicenna Therapeutics Corp flat on Monday (MDNA)Closing Bell: Medicenna Therapeutics Corp flat on Monday (MDNA)
theglobeandmail.com - August 22 at 11:51 AM
MDNA: Commences Monotherapy Dose Expansion in Phase 1/2 ABILITY Trial…MDNA: Commences Monotherapy Dose Expansion in Phase 1/2 ABILITY Trial…
msn.com - August 15 at 4:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

(COV) logo

(COV)

NYSE:COV
Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company's segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company's products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.
Ceapro logo

Ceapro

CVE:CZO
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.
Emerald Health Therapeutics logo

Emerald Health Therapeutics

CVE:EMH
Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.
Medicenna Therapeutics logo

Medicenna Therapeutics

NASDAQ:MDNA
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.